Loss-of-function screens are a powerful way to identify or validate new therapeutic targets. The BPS Bioscience library of CRISPR/Cas9 Kinase Knockout Lentiviruses targets 619 human kinases and pseudo-kinases.
BPS’s new library of CRISPR/Cas9 Kinase Knockout Lentiviruses targets 619 human kinases and pseudo-kinases with 5 single-guide RNAs (sgRNAs) per gene and includes 150 control sgRNAs as well.
These lentiviruses are all-in-one systems that transduce the Cas9 gene along with the sgRNAs targeting the gene of interest. Choose between the full array library, user-defined kinase panels, or individual kinase knockout lentiviruses.
The lentiviruses are replication incompetent, VSV-G pseudotyped lentiviral particles ready to infect almost all types of mammalian cells, including primary and non-dividing cells. The SIN (self-inactivation) lentiviral backbone contains the Cas9 gene (Streptococcus pyogenes CRISPR associated protein 9) driven by an EF1a promoter, an sgRNA driven by a U6 promoter, and a puromycin selection marker.
The lentiviruses integrate randomly into the cellular genome to express both Cas9 and the sgRNAs. Because the lentiviruses contain Cas9, they can be used in any target cell regardless of whether the cells already express Cas9. Puromycin selection ensures high expression of both Cas9 and the sgRNAs. Knockout efficiencies will depend on the cell type and the gene of interest. Stable CRISPR/Cas9 knockout cell lines can also be generated following limiting dilution.
Direct contact technical support
Find products for your research
